Bill Swaim - Nova Eye Pres Ellex
| EYE Stock | 0.15 0.01 6.25% |
Executive
Bill Swaim is Pres Ellex of Nova Eye Medical
| Address | 107 Rundle Street, Kent Town, SA, Australia, 5067 |
| Phone | 61 8 8362 0193 |
| Web | https://www.nova-eye.com |
Nova Eye Management Efficiency
The company has return on total asset (ROA) of (0.1861) % which means that it has lost $0.1861 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3949) %, meaning that it generated substantial loss on money invested by shareholders. Nova Eye's management efficiency ratios could be used to measure how well Nova Eye manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Nova Eye's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 40.5 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 2.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| BCom GDAppFin | Westpac Banking Corp | 54 | |
| Khaidir Said | Aneka Tambang Tbk | 45 | |
| Ismail | Aneka Tambang Tbk | 46 | |
| Peter Chan | Australia and New | N/A | |
| Alexander Bischoff | Westpac Banking Corp | N/A | |
| Rael McNally | Fortescue | N/A | |
| Kevin Corbally | ANZ Group Holdings | 51 | |
| Sweta Mehra | Australia and New | N/A | |
| Polimon Tarigan | Aneka Tambang Tbk | 43 | |
| Isabelle Deschamps | Rio Tinto | 54 | |
| Mahjabeen Zaman | Australia and New | N/A | |
| Navdeep Gill | Fortescue | ||
| Maria Milosavljevic | Australia and New | N/A | |
| Christine Parker | Westpac Banking Corp | 64 | |
| Dino Otranto | Fortescue | N/A | |
| Justin McCarthy | Westpac Banking Corp | N/A | |
| LLB BA | Westpac Banking Corp | 54 | |
| Elisa Clements | Australia and New | N/A | |
| Eamon Harmon | Fortescue | N/A | |
| Philip McKeiver | Fortescue | N/A | |
| Richard BCom | Fortescue | 58 | |
Management Performance
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.19 |
Nova Eye Medical Leadership Team
Elected by the shareholders, the Nova Eye's board of directors comprises two types of representatives: Nova Eye inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nova. The board's role is to monitor Nova Eye's management team and ensure that shareholders' interests are well served. Nova Eye's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nova Eye's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSc FAICD, Advisor Board | ||
| BSc AM, MD Director | ||
| Keith Byrne, Vice Operations | ||
| BEc CA, Company Secretary | ||
| Bill Swaim, Pres Ellex | ||
| Mark Flynn, Investor Relations | ||
| BEng BE, Founder Chairman | ||
| Liam Cook, Chief Officer | ||
| Joaquin Wolff, President iTrack | ||
| Kate Hunt, Head Marketing | ||
| Victor Previn, Founder Chairman | ||
| David MD, Chief Officer | ||
| Kimberley Menzies, Group Manager | ||
| Don Watton, Vice Service |
Nova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nova Eye a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 32.7 M | ||||
| Shares Outstanding | 229.06 M | ||||
| Shares Owned By Insiders | 18.59 % | ||||
| Shares Owned By Institutions | 18.74 % | ||||
| Price To Book | 1.66 X | ||||
| Price To Sales | 1.47 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nova Stock Analysis
When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.